Navigation Links
Genaera Corporation Implements Cash Conservation Plan
Date:3/30/2009

PLYMOUTH MEETING, Pa., March 30 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that it will implement a plan to conserve existing cash resources in order to maintain the ability to pursue business development strategies for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, and explore strategic alternatives. The Company will also actively seek ways to monetize the anti-IL9 antibody (MEDI-528) and pexiganan programs.

The plan will reduce operating expenditures leaving cash resources available for strategic deployment and result in an approximate 80 percent reduction in headcount by May 1, 2009.

"We believe it is prudent to take all appropriate measures to conserve existing capital while weighing our options going forward," commented Jack Armstrong, President and Chief Executive Officer of Genaera.

Genaera estimates that it will incur restructuring charges of approximately $1.3 million in the second quarter of 2009 associated with the reduction in force. As of December 31, 2008, Genaera had cash, cash equivalents and short-term investments of approximately $8.1 million.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as from other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
2. Genaera Corporation Announces 2008 Financial Results
3. Genaera to Present at BIO CEO & Investor Conference
4. Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
5. Genaera to Present at Therapeutic Area Partnerships 2008
6. Genaera Receives Non-Compliance Notice From NASDAQ
7. Genaera Corporations 2008 Annual Stockholder Meeting Results
8. Xmark Comments on Genaera Cost-Saving Plan
9. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
10. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
11. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Campbell, California (PRWEB) , ... ... ... of automated print and e-book publishing software, in partnership with Snowfall4pod Digital, ... AVALANCHE – a comprehensive book publishing, content management, global distribution and print-on-demand ...
(Date:2/9/2016)... WI (PRWEB) , ... February 09, 2016 , ... ... Bergner’s, Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it has ... College of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University of ...
(Date:2/9/2016)... ... 09, 2016 , ... Two renowned photographers, Robert Caplin (New York, NY) and ... island, June 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part ... debut in 2015, the Maui Photo Expedition workshop will once again consist ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... has officially been won. A team from 21st Century Medicine (21CM) ( http://www.21cm.com/ ... to preserve the delicate neural circuits of an intact rabbit brain for extremely ...
(Date:2/8/2016)... LA (PRWEB) , ... February 08, 2016 , ... ... from offices in Houma, LA, celebrates the beginning of a new charity campaign. ... to assist Court Appointed Special Advocates (CASA). In the belief that children deserve ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... The global prefilled syringes market accounted for $3,905.1 million ... with a CAGR of 12.9% during 2015-2020. Among the ... global prefilled syringes market, with 90.1% share in 2014. ... global market of prefilled syringes is up surging with ... demand for vaccines, increasing prevalence of chronic and lifestyle ...
(Date:2/9/2016)... 2016 This TforG report includes the Surgical ... ICD-9 coding system in South Korea ... the report provides written and numerical analysis on the ... In addition, the latest reforms of the local Healthcare ... --> The report helps businesses gain a ...
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson (NYSE: ... Markets Global Healthcare Conference on Tuesday, Feb. 23, at ... Dominic Caruso , Vice President, Finance & Chief Financial ... will represent the Company in a session scheduled at ... --> www.investor.jnj.com . --> This ...
Breaking Medicine Technology: